Learn
Medical EducationEvidence-Based MedicinePatient Education
ICU Toolkit
CalculatorsProtocols & CardsICU Setup
CPT & BillingZad TalkForumContact
Home / Calculators / VV-ECMO Criteria Calculator

VV-ECMO Criteria Calculator

Checks a patient’s blood gas and ventilator status against the entry criteria of the EOLIA trial and the indications in the ELSO 2021 VV-ECMO guideline for severe ARDS.

Arterial blood gas

%
VV-ECMO Criteria
Fill in the fields above to see the result.

How to read the result

Criteria setWhat has to be true
EOLIA (any one; ventilated under 7 days)P/F below 50 mmHg for over 3 hours, or below 80 mmHg for over 6 hours, on FiO2 0.8 or more with tidal volume set at 6 mL/kg and a trial of PEEP 10 cmH2O or more. Or pH below 7.25 with PaCO2 60 mmHg or more for over 6 hours, with the rate raised to 35/min and plateau pressure kept at 32 cmH2O or less.
ELSO 2021 (any one)P/F below 80 mmHg after optimal care, including a prone trial unless contraindicated; pH below 7.25 with PaCO2 60 mmHg or more despite optimal ventilation (rate 35/min, plateau 30 cmH2O or less); bridge to lung transplant or primary graft dysfunction.

“Met” means the criteria for considering VV-ECMO are present, not that cannulation should follow; ELSO states its guidance does not replace medical judgment and the multidisciplinary decision on ECMO.

Criteria

P/F = PaO2 (mmHg) ÷ FiO2 (as a fraction)

PaO2 in kPa × 7.5 gives mmHg. For the hypercapnic criterion EOLIA lowered tidal volume in 1 mL/kg steps to 4 mL/kg, then PEEP to no less than 8 cmH2O, to keep plateau pressure at 32 cmH2O or less. EOLIA also excluded, among others, pregnancy, BMI above 45, chronic respiratory failure on long-term oxygen or ventilation, cardiac failure needing VA-ECMO, prior heparin-induced thrombocytopenia and a SAPS II above 90.

Before ECMO, ELSO asks for evidence-based ARDS care: low tidal volume ventilation (4-6 mL/kg PBW) and prone positioning unless contraindicated, with no delay once ECMO is indicated. ESICM 2023 recommends prone positioning for moderate to severe ARDS (P/F below 150 mmHg) and recommends against routine continuous infusions of neuromuscular blockers. ELSO’s only absolute contraindication is expected non-recovery without a plan for decannulation; its relative contraindications are central nervous system hemorrhage, significant or irreversible incapacitating CNS injury or disease, systemic bleeding, contraindication to anticoagulation, immunosuppression, older age (no cut-off set) and ventilation for over 7 days with plateau pressure above 30 cmH2O and FiO2 above 90%.

Evidence

In EOLIA, 249 patients with very severe ARDS were randomized to immediate VV-ECMO or conventional care with rescue ECMO; 60-day mortality was 35% against 46% (relative risk 0.76, P=0.09), and 28% of controls crossed over to ECMO. CESAR found better survival without severe disability after referral to an ECMO center (63% against 47%). Pooling both trials, the ESICM 2023 guideline found lower 60-day mortality with VV-ECMO (RR 0.72) and strongly recommends ECMO for severe ARDS meeting EOLIA criteria, in an ECMO center that meets defined organizational standards, with management like EOLIA’s.

References

  1. Combes A, Hajage D, Capellier G, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. N Engl J Med. 2018;378(21):1965-1975. PMID 29791822
  2. Extracorporeal membrane oxygenation (ECMO) for severe acute respiratory distress syndrome (ARDS) (EOLIA): eligibility criteria. ClinicalTrials.gov. NCT01470703
  3. Tonna JE, Abrams D, Brodie D, et al. Management of adult patients supported with venovenous extracorporeal membrane oxygenation (VV ECMO): guideline from the Extracorporeal Life Support Organization (ELSO). ASAIO J. 2021;67(6):601-610. PMID 33965970
  4. Grasselli G, Calfee CS, Camporota L, et al. ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies. Intensive Care Med. 2023;49(7):727-759. PMID 37326646
  5. Peek GJ, Mugford M, Tiruvoipati R, et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet. 2009;374(9698):1351-1363. PMID 19762075
Keep reading

Related articles

All Pulmonary →